BRONCHIOLITIS OBLITERANS SYNDROME (BOS)

Clinical trials for BRONCHIOLITIS OBLITERANS SYNDROME (BOS) explained in plain language.

Never miss a new study

Get alerted when new BRONCHIOLITIS OBLITERANS SYNDROME (BOS) trials appear

Sign up with your email to follow new studies for BRONCHIOLITIS OBLITERANS SYNDROME (BOS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Completed 1

New hope for deadly lung complication after transplant

Disease control Recruiting now

This study is testing whether adding the drug Nintedanib to standard treatment is safe and tolerable for patients who develop severe lung scarring (BOS) after a stem cell transplant. The trial will enroll 20 participants who will take Nintedanib daily for 12 months. Researchers w…

Matched conditions: BRONCHIOLITIS OBLITERANS SYNDROME (BOS)

Phase: PHASE2 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control

Last updated Mar 16, 2026 15:26 UTC

BRONCHIOLITIS OBLITERANS SYNDROME (BOS)

Get alerted when new BRONCHIOLITIS OBLITERANS SYNDROME (BOS) trials appear

New hope for deadly lung complication after transplant